Sidra Medicine Signs MoU with Builders VC MENA to Advance Healthcare Innovation

Sidra Medicine has signed a Memorandum of Understanding (MoU) with Builders VC MENA.

The MoU is aimed at strengthening collaboration in healthcare innovation, supporting the development of emerging medical technologies, and expanding partnership opportunities between medical research ecosystems and healthcare-focused venture investment.

Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine said: “We are excited to embark on this partnership with Builders VC MENA, as part of Sidra Medicine’s Innovation Lab strategy. Over the past year, we have worked internally to set up a living lab where biotech and health-tech innovations can meet and work on addressing real world healthcare challenges. Such initiatives will pave the way for win-win public-private partnerships. We are glad to onboard Builders VC as our latest partner on this journey, as we strive to bridge their expertise and network with our people, patients and platforms, creating novel solutions of tangible value for Qatar and beyond.”

The MoU establishes a framework for exploring collaboration between the two parties to bridge venture-backed innovation with clinical application. This includes introducing early stage startups and advanced technologies into Qatar’s healthcare ecosystem, as well as supporting and accelerating research-driven innovations originating from Sidra Medicine toward commercialization, investment pathways, and global scaling.

Tarik Sultan, Partner and Head of Builders VC MENA said: “Healthcare and life sciences are central to Builders VC’s investment strategy, and this MoU formalises what we have been building together over the past year. Sidra Medicine offers our healthtech portfolio companies something rare — world-class clinical infrastructure combined with a research-driven ecosystem where solutions can be validated and deployed with real-world impact. In parallel, the partnership creates a clear pathway for Sidra Medicine’s innovations to access capital, commercialisation opportunities, and global markets. This is exactly the kind of collaboration we came to Qatar to build.”

The collaboration, part of Sidra Medicine’s Innovation Lab remit, which was further strengthened during the sidelines of  Web Summit 2026,  will also focus on advancing solutions that enhance patient outcomes, operational efficiency, and research excellence. It will also enable scientific and commercial validation as well as support regional and international pathways for investment.